Sign in or create an account to add this stock to your watchlist.
About Apellis Pharmaceuticals (NASDAQ:APLS)
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology. The company develops APL-2 for intravitreal injection that is an injection into the eye, as well as subcutaneous injection, which is an injection into the tissue under the skin. It also develops APL-9 for intravenous administration in systemic indications, which is in single ascending dose Phase I clinical trial. Apellis Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Crestwood, Kentucky.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-5.88
Forward P/E Ratio-14.10
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$2.96 per share
Price / Book7.29
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
Apellis Pharmaceuticals (NASDAQ:APLS) Frequently Asked Questions
What is Apellis Pharmaceuticals' stock symbol?
Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."
How were Apellis Pharmaceuticals' earnings last quarter?
Apellis Pharmaceuticals Inc (NASDAQ:APLS) posted its quarterly earnings data on Monday, April, 30th. The company reported ($0.43) EPS for the quarter, missing the Zacks' consensus estimate of ($0.33) by $0.11. View Apellis Pharmaceuticals' Earnings History.
What price target have analysts set for APLS?
4 brokers have issued 12 month price objectives for Apellis Pharmaceuticals' stock. Their predictions range from $23.00 to $35.00. On average, they anticipate Apellis Pharmaceuticals' share price to reach $28.3333 in the next twelve months. View Analyst Ratings for Apellis Pharmaceuticals.
Who are some of Apellis Pharmaceuticals' key competitors?
Some companies that are related to Apellis Pharmaceuticals include Catalent (CTLT), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Hutchison China MediTech (HCM), GW Pharmaceuticals (GWPH), FibroGen (FGEN), Ligand Pharmaceuticals (LGND), Blueprint Medicines (BPMC), Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE) and Amicus Therapeutics (FOLD).
Who are Apellis Pharmaceuticals' key executives?
Apellis Pharmaceuticals' management team includes the folowing people:
- Dr. Cedric Francois M.D., Ph.D., Co-Founder, Pres, CEO & Director (Age 46)
- Dr. Pascal Deschatelets Ph.D., Co-Founder & COO (Age 48)
- Mr. David O. Watson Esq., J.D., Gen. Counsel & VP of Corp. Devel. (Age 45)
- Dr. Federico Grossi M.D., Ph.D., Co-Founder & Sr. VP of Clinical Devel. (Age 44)
- Mr. Alec Machiels J.D., MBA, Co-Founder & Director (Age 45)
When did Apellis Pharmaceuticals IPO?
(APLS) raised $150 million in an IPO on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO.
When did Apellis Pharmaceuticals' lock-up period expire?
Apellis Pharmaceuticals' lock-up period expired on Tuesday, May 8th. Apellis Pharmaceuticals had issued 10,714,000 shares in its public offering on November 9th. The total size of the offering was $149,996,000 based on an initial share price of $14.00. Since the expiration of Apellis Pharmaceuticals' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.
Has Apellis Pharmaceuticals been receiving favorable news coverage?
Headlines about APLS stock have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Apellis Pharmaceuticals earned a news impact score of 0.14 on Accern's scale. They also gave news articles about the company an impact score of 47.81 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are Apellis Pharmaceuticals' major shareholders?
Apellis Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.98%), Sofinnova Ventures Inc (1.63%), Victory Capital Management Inc. (0.67%), Candriam Luxembourg S.C.A. (0.22%), Northern Trust Corp (0.21%) and Russell Investments Group Ltd. (0.09%). View Institutional Ownership Trends for Apellis Pharmaceuticals.
Which institutional investors are buying Apellis Pharmaceuticals stock?
APLS stock was bought by a variety of institutional investors in the last quarter, including Sofinnova Ventures Inc, Victory Capital Management Inc., BlackRock Inc., Russell Investments Group Ltd., New York State Common Retirement Fund, Rhumbline Advisers, Candriam Luxembourg S.C.A. and MetLife Investment Advisors LLC. View Insider Buying and Selling for Apellis Pharmaceuticals.
How do I buy shares of Apellis Pharmaceuticals?
Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Apellis Pharmaceuticals' stock price today?
One share of APLS stock can currently be purchased for approximately $21.57.
How big of a company is Apellis Pharmaceuticals?
Apellis Pharmaceuticals has a market capitalization of $1.38 billion. The company earns $-51,000,000.00 in net income (profit) each year or ($3.67) on an earnings per share basis. Apellis Pharmaceuticals employs 39 workers across the globe.
How can I contact Apellis Pharmaceuticals?
Apellis Pharmaceuticals' mailing address is 6400 WESTWIND WAY SUITE A, CRESTWOOD KY, 40014. The company can be reached via phone at 502-241-4114 or via email at [email protected]
MarketBeat Community Rating for Apellis Pharmaceuticals (APLS)MarketBeat's community ratings are surveys of what our community members think about Apellis Pharmaceuticals and other stocks. Vote "Outperform" if you believe APLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Apellis Pharmaceuticals (NASDAQ:APLS) Earnings History and Estimates Chart
Apellis Pharmaceuticals (NASDAQ:APLS) Earnings Estimates
Current Year EPS Consensus Estimate: $-1.53 EPS
Next Year EPS Consensus Estimate: $-1.74 EPS
Apellis Pharmaceuticals (NASDAQ APLS) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Apellis Pharmaceuticals (NASDAQ:APLS) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Apellis Pharmaceuticals (NASDAQ APLS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.30%
Institutional Ownership Percentage: 30.32%
Apellis Pharmaceuticals (NASDAQ APLS) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|11/13/2017||Global Strategic Fund I Venbio||Major Shareholder||Buy||127,515||$14.00||$1,785,210.00|| |
Apellis Pharmaceuticals (NASDAQ APLS) News Headlines
Apellis Pharmaceuticals (NASDAQ:APLS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Apellis Pharmaceuticals (NASDAQ:APLS) Income Statement, Balance Sheet and Cash Flow Statement
Apellis Pharmaceuticals (NASDAQ APLS) Stock Chart for Tuesday, May, 22, 2018